Press Releases April 23, 2026 04:01 PM

Weight Watchers Schedules First Quarter 2026 Earnings Conference Call

Weight Watchers Announces Q1 2026 Earnings Release and Conference Call Date

By Caleb Monroe WW
Weight Watchers Schedules First Quarter 2026 Earnings Conference Call
WW

WW International, Inc., the leader in science-backed weight management, announced it will release its first quarter 2026 earnings before market open on May 7, 2026, followed by a conference call to discuss results. The company continues to emphasize its integrated, personalized weight management approach, including support for GLP-1 medications and digital/clinical tools.

Key Points

  • WW International to release Q1 2026 earnings on May 7 before market open.
  • Company integrates scientific expertise and GLP-1 medication into weight management programs, addressing a growing healthcare trend.
  • Earnings call webcast available on corporate website, offering transparency to investors and stakeholders.

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the first quarter 2026 ended March 31, 2026, before market open on Thursday, May 7, 2026.

Weight Watchers will host a conference call to discuss results at 8:30 a.m. ET the same day. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

About Weight Watchers
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available on the SEC's EDGAR database at www.sec.gov and via the Company's website at corporate.ww.com).

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

For media inquiries, please contact:
Lizzy Levitan
[email protected]


Risks

  • Forward-looking statements subject to risks and uncertainties as outlined by SEC filings, including variable future results.
  • Potential challenges in adoption or regulatory changes related to GLP-1 medication offerings impacting business model.
  • Competition and market dynamics in the weight management and health technology sectors could affect future performance.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026